Testing single and multiple IV doses of JKN2501 in healthy Chinese adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled, single-center Phase I trial uses single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts to study safety, tolerability, and pharmacokinetics of intravenous JKN2501 in healthy volunteers. Participants are randomly assigned to receive JKN2501 or placebo while biological samples (blood, urine, feces) are collected for PK analysis. Dose levels may be adjusted across cohorts based on emerging safety, tolerability, and PK data, with close monitoring of vital signs, labs, ECGs, and adverse events. The study enrolls adults 18–45 who meet strict inclusion/exclusion criteria and requires attendance at The Third Hospital of Changsha for dosing and follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntary informed consent; able to comply with study requirements and communicate effectively.
* Healthy subjects aged 18-45 years (inclusive) at screening.
* BMI 19.0-26.0 kg/m² (inclusive); weight ≥50 kg (male) or ≥45 kg (female).
* Vital signs, physical examination, ECG, laboratory tests, chest X-ray, and abdominal ultrasound results judged as normal or clinically insignificant by the investigator.
* Agreement to use effective non-pharmaceutical contraception from signing ICF until 90 days after last dose; no sperm/egg donation plans during this period.

Exclusion Criteria:

* Pregnant/lactating women; positive pregnancy test; unprotected sex within 2 weeks prior to dosing.
* Investigator-determined history or presence of clinically significant disorder that may affect safety or trial participation.
* Use of drugs known to inhibit/induce hepatic metabolism within 4 weeks, or any medication (prescription, OTC, herbal, vitamins) within 2 weeks prior to dosing; planned use during the trial.
* Major surgery within 3 months prior to screening or planned during trial; history of surgery potentially affecting results.
* History of febrile illness or active infection within 2 weeks prior to screening.
* Blood loss/donation \>400 mL within 3 months prior to screening, or received blood products; plans to donate blood during trial or within 30 days after last dose.
* History of significant food/drug allergy, or allergy to JKN2501/excipients.
* Excessive alcohol consumption; inability to abstain from alcohol from 48h pre-dose until end of study.
* Smoking ≥5 cigarettes/day within 3 months prior to screening; inability to abstain from smoking from 48h pre-dose until end of study.
* History of drug abuse; positive urine drug screen at baseline (Day -1).
* Positive alcohol breath test at baseline (Day -1).
* Participation in another interventional clinical trial within 3 months prior to screening or planned during this trial.
* Estimated glomerular filtration rate (eGFR) \<90 mL/min.
* Serum total calcium below lower limit of normal at screening.
* Investigator-determined unsuitable venous access for PK sampling/infusion, or history of adverse symptoms/phobias related to infusion/phlebotomy.
* Excessive daily intake of tea, coffee, or caffeinated beverages within 3 months prior to screening.
* Consumption of grapefruit, Seville oranges, caffeine, or xanthine-rich foods/beverages within 48h prior to first dose; inability to abstain during the trial.
* History of QTc prolongation; or investigator-determined clinically significant ECG abnormalities at screening/baseline.
* Any other condition deemed by the investigator to make the subject unsuitable for participation.

Where it's running

• The Third hospital of Changsha
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Yin Yang
• Email: overseas@joincare.com
• Phone: +86-0755-33268688

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using fosfomycin to treat severely infected patients

  This study is testing if an intravenous antibiotic called fosfomycin can safely help people with serious infections like osteomyelitis and bacterial meningitis feel better.

  Recruiting at 45 sites Infectopharm Arzneimittel GmbH · Hall in Tirol and 49 other locations · NCT02979951

• Comparing intravenous and oral antibiotics for acute infections

  This study tests if oral antibiotics can work just as well as intravenous ones for people in the hospital with acute infections to see if they can shorten hospital stays and lower risks.

  Recruiting at 4 sites University of Southern Denmark · Aabenraa, Southern Denmark and 6 other locations · NCT06715306

• Baloxavir for preventing flu after exposure in household contacts

  A single dose of baloxavir marboxil is being tested to see if it prevents symptomatic, lab-confirmed influenza in people who live with someone who has flu symptoms.

  Recruiting at 8 sites Phase 3 Hoffmann-La Roche · Guangzhou, Guangdong and 7 other locations · NCT07827599

• CTX-187 first-in-human test in healthy people and people with chronic bronchiectasis and Pseudomonas infection

  This study tests CTX-187 to see if it is safe and tolerable when given as IV infusions to healthy adults and adults with chronic bronchiectasis and Pseudomonas aeruginosa infection.

  Recruiting Phase 1 Centauri Therapeutics Limited · Groningen · NCT07708116

• Gentamicin Irrigation and Suction Ureteral Access in Kidney Stone Surgery

  This trial tests whether using gentamicin-containing irrigation fluid and a suction-enabled ureteral access sheath during retrograde intrarenal surgery (RIRS) can lower fever, SIRS, and sepsis after kidney stone treatment.

  Recruiting Hitit University · Çorum, Çorum and 1 other locations · NCT07655050

• Gepotidacin in Breast Milk of Healthy Lactating Women

  This study will test how gepotidacin behaves in the breast milk of healthy lactating women who are breastfeeding.

  Recruiting Phase 1 GlaxoSmithKline · Las Vegas, Nevada · NCT07645235

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.